Bharat Biotech's Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.
In line with the government's vision of 'Aatmanirbhar Bharat', the ministry of defence on Thursday signed contracts with Indian shipyards for the acquisition of 11 next generation offshore patrol vessels and six next generation missile vessels at a cost of nearly Rs 19,600 crore, officials said.
The company claims that when the Nitric Oxide Nasal is sprayed over nasal mucosa it acts as a physical and chemical barrier against the virus.
The United States intelligence community has failed to reach any firm conclusion on the exact origin of COVID-19 and is split on whether it leaked from a lab in China or emerged in nature, even though it does not believe the virus was developed as a biological weapon, according to results of a detailed review ordered by President Joe Biden.
The Reserve Bank of India has on Wednesday lifted the ban on new customer acquisition by American Express which was imposed with effect from May 2021 due to non-compliance with local data storage norms. "In view of the satisfactory compliance demonstrated by American Express Banking Corp. with the Reserve Bank of India (RBI) circular dated April 6, 2018, on Storage of Payment System Data, the restrictions imposed, vide order dated April 23, 2021, on onboarding of new domestic customers have been lifted with immediate effect," RBI said. Similar bans were imposed on Diners Club International and Mastercard previously.
'These number surges will be the outcome of emerging virus variants, loss of vaccine- or infection-acquired protective immunity in people, and environmental factors'
'Given that the globally most prevalent clade of SARS-CoV-2 is also predominant in India, any vaccine or drug that gets developed in the world should also prove effective in India'
There is no word yet on the progress of rescue operations for the accommodation barge SS-3 and the Sagar Bhushan oil rig.
The researchers found an increased risk of deep vein thrombosis -- a blood clot in the leg -- up to three months after COVID-19 infection, pulmonary embolism -- a blood clot in the lung -- up to six months, and a bleeding event up to two months.
'We seem to be in a situation where we can do little, and nothing needs to be done anyway.'
The new and highly transmissible Omicron variant of the deadly coronavirus has increased immune escape compared with the Delta variant and appears likely to become the dominant SARS-CoV-2 strain globally in 2022, according to Singapore-based experts.
"The intelligence community and the rest of the government are still looking at this. There's not been a definitive conclusion, so it's difficult for me to say, nor should I feel like I should have to defend press reporting about a possible preliminary indication here," National Security Council Coordinator for Strategic Communications John Kirby told reporters at a daily White House news conference.
The team led by researchers at the University of Maryland in the United States found that people infected with SARS-CoV-2 exhale infectious virus in their breath, and those infected with the Alpha variant put 43 to 100 times more virus into the air than people infected with the original strains of the virus.
BA.4 and BA.5 are sub-variants of the highly-transmissible Omicron variant of the virus.
The ICMR claimed that no country has yet reported successful isolation and culture of the UK-variant of SARS-CoV-2.
The research, published in the journal Scientific Reports, provided the first experimental evidence on the capacity of SARS-CoV-2, the virus that causes COVID-19 disease, to infect and be transmitted by mosquitoes.
A new variant of SARS-CoV-2, the virus which cause COVID-19, has been detected in South Africa and many other countries globally which could be more transmissible and evade protection provided by vaccines, according to study.
A 29-year-old NRI who recently came to Vadodara in Gujarat from South Africa has been found infected with the BA.5 sub-variant of the highly-transmittable Omicron variant of coronavirus, a health official said on Tuesday.
The findings, published in the Journal of Medical Virology, indicate that some of these products might be useful for reducing the viral load, or amount of virus, in the mouth after infection.
Maharashtra has recorded a 17.7 per cent rise in coronavirus cases compared to last week, according to a state health department bulletin.
The new report highlights how different parts of the intelligence community have arrived at disparate judgments about the pandemic's origin.
The endemic stage is when a population learns to live with a virus. It is very different from the epidemic stage when the virus overwhelms a population.
'The ICMR and Biological E Limited, Hyderabad, have developed highly purified antisera (raised in animals) for prophylaxis and treatment of COVID-19,' the apex health research body said on Thursday. The 'antisera' is yet to undergo human clinical trials to establish its safety and efficacy and Drugs Controller General of India would be approached soon in this regard, Dr Samiran Panda, the head of epidemiology and communicable diseases at the ICMR said.
ZyCoV-D is a three-dose vaccine administered intradermally.
Covaxin, a whole-virion inactivated SARS-CoV-2 vaccine used for mass immunization in the country, showed a 65.2 per cent protection against the Delta variant in a double-blind, randomized, multicentre, phase 3 clinical trial.
'Delta continues to be the dominant lineage for new cases across all parts of India in recent samples and remains the most rapidly rising lineage globally that is responsible for multiple outbreaks, including across Southeast Asia, which shows the fastest growth in new cases globally,' the INSACOG said.
The rapid molecular test is highly accurate and easy to use, making it a prime candidate for use in settings with limited testing capabilities, according to the researchers.
Named after Satyajit Ray's famed detective, the Feluda test, which is priced at Rs 500 and can deliver a result in 45 minutes, is able to differentiate SARS-CoV-2 from other coronaviruses even if genetic variations between them are minute.
The global health agency has asked Chinese health officials to share data on genetic sequencing, hospitalisations, deaths and vaccinations.
The durability of immunity post COVID-19 vaccination persists for nine months or more and a precautionary dose of vaccine which will be administered to healthcare and frontline workers and citizens above 60 years with comorbidities is to mitigate the severity of infection, hospitalisation and death, the government said on Thursday.
"We continue to call on China to be transparent in sharing data and to conduct the necessary investigations and share the results. Understanding how the pandemic began remains both a moral and scientific imperative," Ghebreyesus said.
'If there are any symptoms/variants of concern, states can prepare accordingly.'
The 'antisera' has been developed by the ICMR in collaboration with a Hyderabad-based bio-pharmaceutical firm. "With Biological E Limited we have developed an horse 'antisera' and we have just got clearance for conducting clinical trials for that," ICMR Director General Dr Balram Bhargava said at press briefing.
The first nasal vaccine against COVID-19, developed by Bharat Biotech, has received regulator's nod for conducting phase 2 clinical trials, the Department of Biotechnology said on Friday.
The World Health Organisation said in its latest update that the XE recombinant (BA.1-BA.2) was first detected in the UK on January 19 and more than 600 sequences have been reported and confirmed since then.
India is shining, although I will argue that it is a temporary acceptance until India once again makes a mega-successful film like RRR or another beautiful, moving, documentary like The Elephant Whisperers, notes Aseem Chhabra.
The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the United Kingdom and India, respectively.
The vaccine was well tolerated in all dose groups with no vaccine-related adverse events.
Results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.
But no extra risk after second dose, shows study led and funded by drug maker, reports Sohini Das.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances